Choline Fenofibrate/Rosuvastatin Calcium

非诺贝特胆碱/瑞舒伐他汀钙

Report date: 2022/06/28 10:59:05

Base Information

Drug NameCholine Fenofibrate/Rosuvastatin Calcium
Drug Alias NameRosuvastatin/Choline Fenofibrate瑞舒伐他汀钙/非诺贝特胆碱Choline Fenofibrate/RosuvastatinRosuvastatin Calcium/Choline FenofibrateCertriad +[6] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor αHMG-CoA reductase
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsHyperlipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Choline FenofibrateRosuvastatin Calcium
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca PlcAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAstrazeneca Pharmaceutical Co LtdAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsHyperlipidemias

Other Information

ATC CodeN/A
Related LinksN/A